Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?

With a market cap of $124.4 billion, Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company that discovers, develops, manufactures, and markets innovative medicines worldwide. Its portfolio spans key therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, with well-known products such as Opdivo, Eliquis, Revlimid, and Yervoy. Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and Bristol-Myers Squibb fi ...